Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Dementia expert considers an Amyloid-scan appropriate according to Amyloid-imaging task force criteria (AIT) after conference with an Amyloid-PET expert~* Preambles of the AIT-Criteria are fulfilled~  1. A cognitive complaint with objectively confirmed impairment~ 2. AD as a possible diagnosis, but when the diagnosis is uncertain after a comprehensive evaluation by a dementia expert~ 3. When knowledge of the presence or absence of Abeta pathology is expected to increase diagnostic certainty and alter Management~  <!-- -->~  1. Patients with persistent or progressive unexplained MCI~ 2. Patients satisfying core clinical criteria for possible AD because of unclear clinical presentation, either an atypical clinical course or an etiologically mixed presentation~ 3. Patients with progressive dementia and atypically early age of onset (65 years or less in age)~ 4. other situations where preambles of AIT-Criteria are fulfilled~* Diagnosis was established in a memory clinic or by an experienced physician in dementia diagnostics~* The diagnostic procedures comprise in minimum MRI, neuropsychology, routine blood test for exclusion of symptomatic causes~* MMSE \>15~* Competency to consent~* Trial partner willing to support study physician~* Written informed consent by both patient and trial partner~* Understanding of German language~* Treating physician willing to collaborate with the study team~Exclusion Criteria:~* Cognitive impairment which can be attributed to another underlying medical condition that renders a possibility of Alzheimer's disease very unlikely (thus violating preamble B)~* Clinically significant Depression (decided upon clinical assessment)~* MRI exclusion criteria~* PET exclusion criteria~  1. Allergy to Flutemetamol or any of the excipients of the solution for injections~ 2. History of severe allergic reactions to drugs or allergens~ 3. Pregnancy or lactation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Flutmetamol Group (Type: EXPERIMENTAL): PET-MR-Scan with 80-140 MBq Flutemetamol before observational period for diagnostic purpose

Based on this trial design, predict the completion outcome and termination type (if applicable).